Browsing Clinical Studies by author "Judson, Ian"
Now showing items 1-20 of 29
-
Absence of progression, not extent of tumour shrinkage, defines prognosis in soft-tissue sarcoma - An analysis of the EORTC 62012 study of the EORTC STBSG.
Grünwald, V; Litière, S; Young, R; Messiou, C; Lia, M; et al. (2016-09)Background Anthracycline-based chemotherapy remains the mainstay of first-line treatment in metastatic or advanced soft-tissue sarcoma (STS). Age, performance status, tumour histology and tumour grade are recognised ... -
Aggressive fibromatosis response to tamoxifen: lack of correlation between MRI and symptomatic response.
Libertini, M; Mitra, I; van der Graaf, WTA; Miah, AB; Judson, I; et al. (2018-01)Background One of the commonly used systemic agents for the treatment of aggressive fibromatosis is the anti-oestrogen drug tamoxifen. However, data on efficacy and optimum methods of response assessment are limited, ... -
An update on the management of sporadic desmoid-type fibromatosis: a European Consensus Initiative between Sarcoma PAtients EuroNet (SPAEN) and European Organization for Research and Treatment of Cancer (EORTC)/Soft Tissue and Bone Sarcoma Group (STBSG).
Kasper, B; Baumgarten, C; Garcia, J; Bonvalot, S; Haas, R; et al. (2017-10)Desmoid-type fibromatosis is a rare and locally aggressive monoclonal, fibroblastic proliferation characterized by a variable and often unpredictable clinical course. Currently, there is no established or evidence-based ... -
Axitinib in patients with advanced/metastatic soft tissue sarcoma (Axi-STS): an open-label, multicentre, phase II trial in four histological strata.
Woll, PJ; Gaunt, P; Gaskell, C; Young, R; Benson, C; et al. (SPRINGERNATURE, 2023-10-26)BACKGROUND: Axitinib is an oral vascular endothelial growth factor receptor inhibitor with anti-tumour activity in renal, thyroid, and pancreatic cancer. METHODS: Axi-STS was a pathologically-stratified, non-randomised, ... -
Controversies in the management of patients with soft tissue sarcoma: Recommendations of the Conference on State of Science in Sarcoma 2022.
Rothermundt, C; Andreou, D; Blay, J-Y; Brodowicz, T; Desar, IME; et al. (ELSEVIER SCI LTD, 2022-11-16)BACKGROUND: Owing to the rarity and heterogeneity in biology and presentation, there are multiple areas in the diagnosis, treatment and follow-up of soft tissue sarcoma (STS), with no, low-level or conflicting evidence. ... -
Diagnosis and management of tropomyosin receptor kinase (TRK) fusion sarcomas: expert recommendations from the World Sarcoma Network.
Demetri, GD; Antonescu, CR; Bjerkehagen, B; Bovée, JVMG; Boye, K; et al. (2020-11)Sarcomas are a heterogeneous group of malignancies with mesenchymal lineage differentiation. The discovery of neurotrophic tyrosine receptor kinase (NTRK) gene fusions as tissue-agnostic oncogenic drivers has led to new ... -
Does palliative chemotherapy really palliate and are we measuring it correctly? A mixed methods longitudinal study of health related quality of life in advanced soft tissue sarcoma.
Gough, N; Koffman, J; Ross, JR; Riley, J; Judson, I (2019-01)OBJECTIVE:Soft tissue sarcoma (STS) is a rare cancer type that when locally advanced or metastatic, is predominantly treated with palliative chemotherapy with the aim of improving both quantity and quality of life. Given ... -
Gene expression profiling identifies distinct molecular subgroups of leiomyosarcoma with clinical relevance.
Lee, Y-F; Roe, T; Mangham, DC; Fisher, C; Grimer, RJ; et al. (2016-10)Background Soft tissue sarcomas are heterogeneous and a major complication in their management is that the existing classification scheme is not definitive and is still evolving. Leiomyosarcomas, a major histologic category ... -
High-Dose Chemotherapy Compared With Standard Chemotherapy and Lung Radiation in Ewing Sarcoma With Pulmonary Metastases: Results of the European Ewing Tumour Working Initiative of National Groups, 99 Trial and EWING 2008.
Dirksen, U; Brennan, B; Le Deley, M-C; Cozic, N; van den Berg, H; et al. (2019-12)PURPOSE:The R2Pulm trial was conducted to evaluate the effect of busulfan-melphalan high-dose chemotherapy with autologous stem-cell rescue (BuMel) without whole-lung irradiation (WLI) on event-free survival (main end ... -
Impact of chemotherapy in uterine sarcoma (UtS): review of 13 clinical trials from the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) involving advanced/metastatic UtS compared to other soft tissue sarcoma (STS) patients treated with first line chemotherapy.
Ray-Coquard, I; Rizzo, E; Blay, JY; Casali, P; Judson, I; et al. (2016-07)Objective UtS are a group of uncommon tumors representing 1% of malignant neoplasms of the female genital tract, and 7% of sarcomas. The objective of this study was to evaluate the factors associated with the clinical ... -
Outcome of uterine sarcoma patients treated with pazopanib: A retrospective analysis based on two European Organisation for Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group (STBSG) clinical trials 62043 and 62072.
Benson, C; Ray-Coquard, I; Sleijfer, S; Litière, S; Blay, J-Y; et al. (2016-07)Background Uterine sarcomas are a group of mesenchymal tumours comprising several histologies. They have a high recurrence rate following surgery, modest outcome to systemic therapy, and poor overall survival. Pazopanib ... -
p.(L576P) -KIT mutation in GIST: Favorable prognosis and sensitive to imatinib?
Noujaim, J; Gonzalez, D; Thway, K; Jones, RL; Judson, I (2016-05)Exon 11 KIT mutations are found in a majority of gastrointestinal stromal tumors (GIST) and are usually predictive of response to imatinib, a KIT, PDGFRA and ABL inhibitor. Exon 11 mutations with poor sensitivity to imatinib ... -
Pazopanib, a promising option for the treatment of aggressive fibromatosis.
Szucs, Z; Messiou, C; Wong, HH; Hatcher, H; Miah, A; et al. (2017-04)Desmoid tumour/aggressive fibromatosis (DT/AF) is a rare soft-tissue neoplasm that is locally aggressive but does not metastasize. There is no standard systemic treatment for symptomatic patients, although a number of ... -
Predictive and prognostic factors associated with soft tissue sarcoma response to chemotherapy: a subgroup analysis of the European Organisation for Research and Treatment of Cancer 62012 study.
Young, RJ; Litière, S; Lia, M; Hogendoorn, PCW; Fisher, C; et al. (2017-07)Background The European Organization for Research and Treatment of Cancer (EORTC) 62012 study was a Phase III trial of doxorubicin versus doxorubicin-ifosfamide chemotherapy in 455 patients with advanced soft tissue sarcoma ... -
Predictors for doxorubicin-induced hematological toxicity and its association with outcome in advanced soft tissue sarcoma patients; a retrospective analysis of the EORTC-soft tissue and bone sarcoma group database.
Sleijfer, S; Rizzo, E; Litière, S; Mathijssen, RHJ; Judson, IR; et al. (2018-08)INTRODUCTION:As both anti-tumour effects and toxicity are thought to be dose-dependent, patients with the greatest toxicity may also have the best outcome. We assessed whether severity of doxorubicin-induced hematological ... -
Prognostic Significance of Bone Metastasis in Soft Tissue Sarcoma Patients Receiving Palliative Systemic Therapy: An Explorative, Retrospective Pooled Analysis of the EORTC-Soft Tissue and Bone Sarcoma Group (STBSG) Database.
Kantidakis, G; Litière, S; Gelderblom, H; Fiocco, M; Judson, I; et al. (Hindawi Limited, 2022-04-01)Background: Soft-tissue sarcomas (STS) constitute a rare group of heterogeneous mesenchymal tumours containing more than 100 histologic subtypes. Here, we investigate whether, and if so, to what extent, skeletal metastases ... -
Safety and efficacy of Pazopanib in advanced soft tissue sarcoma: PALETTE (EORTC 62072) subgroup analyses.
Cesne, AL; Bauer, S; Demetri, GD; Han, G; Dezzani, L; et al. (2019-08-13)Background PALETTE is a phase 3 trial that demonstrated single-agent activity of pazopanib in advanced soft tissue sarcomas (aSTS). We performed retrospective subgroup analyses to explore potential relationships between ... -
Sarcoma: Olaratumab - really a breakthrough for soft-tissue sarcomas?
Judson, I; van der Graaf, WT (2016-09) -
Soft tissue sarcomas in adolescents and young adults: a comparison with their paediatric and adult counterparts.
van der Graaf, WTA; Orbach, D; Judson, IR; Ferrari, A (2017-03-02)Survival outcomes for adolescent and young adult patients with soft tissue sarcomas lag behind those of children diagnosed with histologically similar tumours. To help understand these differences in outcomes, we discuss ... -
Surrogate endpoints in advanced sarcoma trials: a meta-analysis.
Savina, M; Litière, S; Italiano, A; Burzykowski, T; Bonnetain, F; et al. (2018-10-02)Background Alternative endpoints to overall survival (OS) are frequently used to assess treatment efficacy in randomized controlled trials (RCT). Their properties in terms of surrogate outcomes for OS need to be assessed. ...